IMAGE: Associate Professor, Department of Infectious Diseases University of Pittsburgh, and director of the UPMC Community Hospital (CHASE) unethical stewardship efforts program. view more
Credit: UPMC
PITTSBURGH, March 26, 2021 – As evidence rises to support the use of monoclonal antibody treatment to hospitalize and deaths from COVID-19, UPMC and physician-scientist University of Pittsburgh School of Medicine share knowledge the health system delivers the life-saving medicine.
In a report published today in the scientific journal Infectious diseases open forum, the UPMC / Pitt team shares how they quickly established the largest and most equitable distribution network for COVID-19 monoclonal antibody inclusion throughout Pennsylvania. The team today also reported initial results confirming the treatment reduced the likelihood of hospitalization and death in UPMC patients who received it.
“When administered shortly after an infection, this treatment can help some people fight the virus and keep them from progressing to serious illness and death,” said Ryan Bariola, MD, senior. associate professor in the Pitt Department of Infectious Diseases and director of UPMC Antimicrobial Community Hospital Stewardship efforts program (CHASE). “But managing these inclusions comes with supply challenges, so so many health care providers are choosing not to offer the treatment. UPMC has overcome these challenges, and we are committed to sharing our learning with other medical institutions, clinicians and the general public. “
Monoclonal – “mono” means “one” and “clonal” means “copy” – antibodies are a type of medicine that looks for the COVID-19 virus in a person’s body and preventing it from invading their cells and reproducing. Since late 2020, the U.S. Food and Drug Administration has granted Emergency Use Authorization (EUA) to three monoclonal antibody therapies – one from Regeneron and two from Eli Lilly – that are administered through a one-time IV infusion. This is the same type of emergency license granted for the COVID-19 vaccines given in the US
This treatment is very helpful when given early, especially within 10 days of infections in people at greatest risk of complications from COVID-19.
The U.S. supply of monoclonal antibodies is funded by taxpayers and provided free of charge to the institutions that administer it. In preparation for high patient demand, UPMC created a weighted lottery to ensure a fair distribution of its provision. However, demand has never been high enough to encourage the use of the lottery.
“This lower practice surprised us, and we are still debating why demand was lower than expected,” said co-author Donald M. Yealy, MD, UPMC chief medical officer and professor and chairman Department of Emergency Medicine Pitt. “It seemed to have to do with so few healthcare providers investing in the infrastructure, staffing and processes needed to deliver the drug. This created lower awareness among both patients and clinicians about the life-saving benefits of monoclonal antibodies. “
Initially, eligibility was limited to patients 65 years or older, or to those with a body mass index of at least 35 because those were the people identified by studies who were more likely to benefit. UPMC has since expanded its eligibility for younger people with certain medical conditions that put them at greater risk for COVID-19 complications, including children, according to the EUA.
To date, UPMC has treated more than 1,000 patients with monoclonal antibodies at 16 sites across the communities it serves in Pennsylvania and New York. It also provides home infusion services when needed. UPMC ensures that all correct infection prevention protocols are followed, and in particular prevents COVID-19 patients from mixing with other patients at the infusion centers.
“Monoclonal antibodies are an essential part of the COVID-19 treatment spectrum, closing the gap between protective measures – such as masks, social distance and vaccines – and the different treatments for COVID-19 patients in hospital,” said lead author Mark Schmidhofer, MD, professor of medicine at Pitt and medical director of the UPMC Coronary Intensive Care Unit. “It could be a life-saving option and it can keep people out of hospital if a ban fails.”
###
Patients and providers can find out more about monoclonal antibody treatment at UPMC by visiting upmc.com/AntibodyTreatment or calling 866-804-5251.
Additional authors of this research are Erin McCreary, Pharm.D., Tina Khadem, Pharm.D., Graham Snyder, MD, MS, Richard Wadas, MD, David A. Nace, MD, MPH, and Douglas B. White , MD, MAS, Pitt and all UPMC.
To read or share this message online, visit https: /
Contact further:
Danielle Sampsell
Office: 814-889-2622
Mobile: 412-420-9818
Email: [email protected]
About UPMC
Pittsburgh-based $ 23 billion health care provider and insurer UPMC is designing new models of accountable, cost-effective, accountable care. The largest non-governmental employer in Pennsylvania, UPMC includes 92,000 employees, 40 hospitals, 700 physician offices and outpatient sites, and a 4 million-member Department of Insurance Services, the medical insurer largest in western Pennsylvania. In the most recent fiscal year, UPMC contributed $ 1.4 billion in benefits to its communities, providing more care to the most vulnerable citizens than any other health care institution, and paid more than $ 800 million in federal, state and local taxes. Working in close collaboration with the University of Pittsburgh Schools of Health Sciences, UPMC shares its clinical, management and technology skills worldwide through its innovation and commercialization arm, UPMC Enterprises, and through UPMC International . The U.S. News and World Report regularly ranks UPMC Presbyterian Shadyside among the best hospitals in the country in many specialties and runs UPMC Children’s Hospital in Pittsburgh on the best children’s hospitals in America. For more information, visit UPMC.com. ??? ??????
About the University of Pittsburgh School of Medicine
As one of the nation’s leading academic centers for biochemical study, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a wide range of subjects in an ongoing effort to harness the power of new knowledge and improve the human condition . Managed primarily by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In a ranking recently released short with the National Science Foundation, Pitt was ranked fifth among all American federal universities. science and engineering research and development support.
Similarly, the School of Medicine is equally committed to enhancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and for training skilled clinicians. , compassionate and creative scientists with great potential to engage in world-class research. The School of Medicine is an academic partner of UPMC, which has partnered with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region’s economy. For more information about the School of Medicine, see http: // www.
http: // www.